Arcutis Biotherapeutics (ARQT) Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ARQT Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Arcutis Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.57 |
| 52 Week High | US$18.15 |
| 52 Week Low | US$8.03 |
| Beta | 1.94 |
| 1 Month Change | 23.82% |
| 3 Month Change | 30.15% |
| 1 Year Change | 67.02% |
| 3 Year Change | -8.58% |
| 5 Year Change | -31.61% |
| Change since IPO | -19.40% |
Recent News & Updates
Recent updates
Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate
Aug 23Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?
Jul 15
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 09
FDA PDUFA Date And Payer Expansion Will Unlock Opportunity
Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Apr 19Arcutis Biotherapeutics: Topical Derm Player Continues To Execute
Mar 12Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up
Mar 09Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Feb 26Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period
Jan 23Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jan 02There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump
Nov 27Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Shareholder Returns
| ARQT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.2% | -0.5% | 1.4% |
| 1Y | 67.0% | -7.7% | 19.1% |
Return vs Industry: ARQT exceeded the US Biotechs industry which returned -5.8% over the past year.
Return vs Market: ARQT exceeded the US Market which returned 20% over the past year.
Price Volatility
| ARQT volatility | |
|---|---|
| ARQT Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARQT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARQT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 342 | Frank Watanabe | www.arcutis.com |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis.
Arcutis Biotherapeutics, Inc. Fundamentals Summary
| ARQT fundamental statistics | |
|---|---|
| Market cap | US$2.15b |
| Earnings (TTM) | -US$93.27m |
| Revenue (TTM) | US$263.47m |
Is ARQT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARQT income statement (TTM) | |
|---|---|
| Revenue | US$263.47m |
| Cost of Revenue | US$28.73m |
| Gross Profit | US$234.74m |
| Other Expenses | US$328.01m |
| Earnings | -US$93.27m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 89.10% |
| Net Profit Margin | -35.40% |
| Debt/Equity Ratio | 77.7% |
How did ARQT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/10 17:15 |
| End of Day Share Price | 2025/09/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcutis Biotherapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Shibutani | Goldman Sachs |
| Richard J. Law | Goldman Sachs |
| null null | Guggenheim Securities, LLC |